Filter Results:
(1,243)
Show Results For
- All HBS Web
(1,243)
- People (5)
- News (171)
- Research (927)
- Events (6)
- Multimedia (12)
- Faculty Publications (755)
Show Results For
- All HBS Web
(1,243)
- People (5)
- News (171)
- Research (927)
- Events (6)
- Multimedia (12)
- Faculty Publications (755)
- September 2003 (Revised February 2007)
- Case
PolyMedica Corporation (A)
By: David F. Hawkins and Jacob Cohen
The Securities and Exchange Commission and investors question PolyMedica Corp.'s practice of capitalizing rather than expensing of direct-response advertising. View Details
Keywords: Activity Based Costing and Management; Business Earnings; Advertising; Private Sector; Budgets and Budgeting; Cost Management; Capital Markets; Marketing; Private Equity; Pharmaceutical Industry; Pharmaceutical Industry
Hawkins, David F., and Jacob Cohen. "PolyMedica Corporation (A)." Harvard Business School Case 104-023, September 2003. (Revised February 2007.)
- 15 Jan 2013
- First Look
First Look: January 15
and Use of a New Accounting System Authors:Narayanan, V.G., Ranjani Krishnan, and Jamshed J. Mistry Publication:Journal of Management Accounting Research Abstract This study examines the attitudes, use, and acceptance of a new accounting system in a View Details
Keywords: Sean Silverthorne
- 07 Aug 2009
- What Do You Think?
Why Can’t Americans Get Health Care Right?
above are numerous in a channel that includes, in your comments, food and tobacco producers of unhealthy products (Christy Hitchens, Tom Dolembo); lifestyle equipment and service providers; developers and manufacturers of high-cost View Details
- 06 Aug 2001
- Research & Ideas
Go Globalor No? Can You Make the Case?
Remember, we don't yet have the capability to serve the chemical and pharmaceutical industries here. There are still only 38 of us, and I estimate that building the support infrastructure we need just for domestic expansion could cost as... View Details
Keywords: by Walter Kuemmerle
- 18 Jul 2018
- Research & Ideas
No More General Tso's? A Threat to 'Knowledge Recombination'
pharmaceutical companies, which had been flying in scientists from China and India who, like Cohly, brought knowledge of native herbs. Some pharma companies were able to earn exemptions from the H1-B limits. Choudhury and Kim used this... View Details
- 26 Jun 2000
- Research & Ideas
What’s an Internet Business Model? Ask a Health Care Professional
out how to get into a clinical trial to try an experimental drug. For their part, physicians are often befuddled by difficult cases that don't respond to traditional therapies. And pharmaceutical companies, at the same time, are anxious... View Details
- 01 Mar 2003
- News
Naina Lal Kidwai
to the global automobile industry. Biotechnology and pharmaceutical firms are emerging as international players. There are also opportunities in infrastructure investment, such as telecom, ports, roads, and airports. Please comment on... View Details
- 26 Jan 2009
- Research & Ideas
Where is Home for the Global Firm?
you share these ideas? A: Of course, once you write something like this, you come to see many things through these lenses. As reported in the Financial Times in October, several UK firms including Shire Pharmaceuticals and WPP Group have... View Details
Keywords: by Martha Lagace
- 01 Feb 2000
- News
Executives Convene to Discuss Consumer-Driven Health Care
alumni event attracted more than sixty HBS graduates representing biotechnology, e-commerce, managed care, and pharmaceutical companies. The program featured briefings from HBS faculty members interested in issues related to health-care... View Details
- 20 Nov 2006
- Research & Ideas
Open Source Science: A New Model for Innovation
problems that were posted? A: Innovations happen at the intersection of disciplines. People have talked about that a lot and I think we're providing some systematic evidence now with this study. Another example is that a pharmaceutical... View Details
Keywords: by Martha Lagace
- 22 Apr 2014
- First Look
First Look: April 22
constraints. Download working paper: https://www.hbs.edu/faculty/Pages/download.aspx?name=14-097.pdf The Organizational and Geographic Drivers of Absorptive Capacity: An Empirical Analysis of Pharmaceutical R&D Laboratories By:... View Details
Keywords: Sean Silverthorne
- March 2024 (Revised July 2024)
- Case
WeightWatchers: Promoting Weight Health
In December 2023, the 60-year-old weight management industry stalwart WeightWatchers announced the launch of WeightWatchers Clinic, which incorporated GLP-1s , a new class of prescription weight-loss medications, into the company’s portfolio of products and mobile app... View Details
Keywords: Business Strategy; Competitive Strategy; Resource Allocation; Diversification; Leadership; Growth and Development Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; New York (city, NY)
Gulati, Ranjay, Cynthia A. Montgomery, Ashley Whillans, Allison Ciechanover, and Emily Grandjean. "WeightWatchers: Promoting Weight Health." Harvard Business School Case 424-029, March 2024. (Revised July 2024.)
- September 2019
- Case
Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem
By: Willy C. Shih
Vaccines for children has been a long-standing focus for the Bill & Melinda Gates Foundation, and its critical role in public health made its production an important economic and political issue. This case describes the Foundation's investment in a breakthrough vaccine... View Details
Keywords: Vaccine; Production; Supply Chain; Product; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Belgium
Shih, Willy C. "Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem." Harvard Business School Case 620-021, September 2019.
- December 1999
- Case
Agrochemicals at Ciba-Geigy AG (A)
By: Michael L. Tushman, Wendy Smith and Daniel Radov
After spending five years to develop a revolutionary product, the director of Ciba-Geigy's fungicide research department is handed an unfavorable market study. The case details the R&D process for the new product, including information on corporate partnerships,... View Details
Keywords: Agribusiness; Plant-Based Agribusiness; Research and Development; Innovation and Invention; Innovation Strategy; Product Launch; Marketing Channels; Change Management; Product Development; Business Processes; Organizational Structure; Corporate Accountability; Pharmaceutical Industry; Pharmaceutical Industry
Tushman, Michael L., Wendy Smith, and Daniel Radov. "Agrochemicals at Ciba-Geigy AG (A)." Harvard Business School Case 400-022, December 1999.
- March 2010 (Revised May 2012)
- Case
Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration
By: Karim R. Lakhani and Paul R. Carlile
This case presents the Myelin Repair Foundation's accelerated research collaboration model for drug discovery. It highlights the challenges of building a multi-disciplinary and multi-institutional research collaboration that is attempting to create a treatment for... View Details
Keywords: Research and Development; Intellectual Property; Risk and Uncertainty; Strategic Planning; Collaborative Innovation and Invention; Health Disorders; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Lakhani, Karim R., and Paul R. Carlile. "Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration." Harvard Business School Case 610-074, March 2010. (Revised May 2012.)
- 17 Jan 2008
- Working Paper Summaries
Competition in Modular Clusters
- November 2023 (Revised April 2024)
- Case
BiomX: Bringing Phage Back to the Stage
By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Pharmaceutical Industry; Pharmaceutical Industry
Gompers, Paul A., Elie Ofek, Orna Dan, and Emilie Billaud. "BiomX: Bringing Phage Back to the Stage." Harvard Business School Case 524-051, November 2023. (Revised April 2024.)
- March 2015 (Revised September 2016)
- Case
Terrapin Laboratory
By: Richard G. Hamermesh and Joseph B. Fuller
Describes the formation and rapid growth of a drug testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug treatment center business. The associated teaching materials provide students the opportunity... View Details
Keywords: Business Growth; Entrepreneurial Management; Entrepreneurship; Growth Strategy; Market Entry; Venture Capital; Growth Management; Expansion; Financing and Loans; Health Care and Treatment; Health Testing and Trials; Business Startups; Pharmaceutical Industry; Pharmaceutical Industry
Hamermesh, Richard G., and Joseph B. Fuller. "Terrapin Laboratory." Harvard Business School Case 315-098, March 2015. (Revised September 2016.)
- October 2014 (Revised July 2016)
- Supplement
Gilead: Hepatitis C Access Strategy (B)
While the "Gilead: Hepatitis-C Access Strategy (A)" case (HBS No. 515-025) poses questions on what the company should do with respect to hard-hit countries like Egypt and India, the (B) case provides the answer. In both cases, the company chose to pursue a proactive... View Details
Rangan, V. Kasturi. "Gilead: Hepatitis C Access Strategy (B)." Harvard Business School Supplement 515-044, October 2014. (Revised July 2016.)
- January 2014
- Supplement
Amgen Inc.: Pursuing Innovation and Imitation? (B)
By: Ian Mackenzie
The (B) case reveals that Sharer decided that Amgen should enter the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The... View Details
Mackenzie, Ian. "Amgen Inc.: Pursuing Innovation and Imitation? (B)." Harvard Business School Supplement 714-426, January 2014.